Any thoughts on why Cytodyn loaded the plane to attend ESMO in Berlin, but they apparently there will be no participation in ASCO in Chicago? Are they telling us that Europe is preferable to the US for approval of leronlimab? Perhaps ESMO was more appropriate for the poster presentation than ASCO. Was there greater emphasis on Tnbc at ESMO than ASCO? Perhaps management lacks confidence in this iteration of the FDA. Tell us what you think.